Novartis breast cancer drug cuts death risk 19% in trial

Six-year trial data showed Novartis’s Kisqali cut the risk of death by 19% in high-risk early breast cancer. Survival reached 91.9% with Kisqali and hormone therapy versus 89.7% with hormone therapy alone.